Biodesix, Inc.
BDSX
$15.86
$0.563.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 88.50M | 80.17M | 76.56M | 74.46M | 71.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.50M | 80.17M | 76.56M | 74.46M | 71.32M |
| Cost of Revenue | 16.72M | 16.18M | 16.26M | 16.10M | 15.57M |
| Gross Profit | 71.78M | 63.99M | 60.30M | 58.36M | 55.75M |
| SG&A Expenses | 87.55M | 84.79M | 83.09M | 80.34M | 80.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.27M | 112.52M | 110.45M | 106.83M | 105.58M |
| Operating Income | -27.77M | -32.35M | -33.89M | -32.37M | -34.26M |
| Income Before Tax | -35.27M | -39.54M | -41.08M | -40.42M | -42.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.27 | -39.54 | -41.08 | -40.42 | -42.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.27M | -39.54M | -41.08M | -40.42M | -42.93M |
| EBIT | -27.77M | -32.35M | -33.89M | -32.37M | -34.26M |
| EBITDA | -22.10M | -26.61M | -28.08M | -26.58M | -28.49M |
| EPS Basic | -4.73 | -5.37 | -5.61 | -5.74 | -7.03 |
| Normalized Basic EPS | -2.95 | -3.34 | -3.49 | -3.54 | -4.35 |
| EPS Diluted | -4.73 | -5.37 | -5.61 | -5.74 | -7.03 |
| Normalized Diluted EPS | -2.95 | -3.34 | -3.49 | -3.54 | -4.35 |
| Average Basic Shares Outstanding | 30.23M | 29.49M | 29.31M | 28.33M | 25.86M |
| Average Diluted Shares Outstanding | 30.23M | 29.49M | 29.31M | 28.33M | 25.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |